Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Фаза 2/3
Идёт, набор закрыт
NCT04655976
| Заболевание | Lung Cancer, Non-Small Cell |
|---|
| Фаза | Фаза 2/3 |
|---|
| Спонсор | GlaxoSmithKline |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 758 участн. |
|---|
| Вмешательство | Cobolimab, Dostarlimab, Docetaxel |
|---|
| Дата начала | 8.12.2020 |
|---|
| Дата завершения | 5.06.2025 |
|---|
| Публикация результатов | 1.07.2026 |
|---|
Кратко
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Overall Survival (OS) (Arm A Versus Arm C)
Up to approximately 234 weeks · Months
| Cobolimab + Dostarlimab + Docetaxel (Arm A) | 11.9 Months |
|---|
| Docetaxel (Arm C) | 11.3 Months |
|---|
| p-value | 0.079708 |
|---|
| Hazard Ratio (HR) | 0.85 (95% CI 0.68–1.06) |
|---|
Overall Survival (OS) (Arm B Versus Arm C)
Up to approximately 234 weeks · Months
| Dostarlimab + Docetaxel (Arm B) | 11.8 Months |
|---|
| Docetaxel (Arm C) | 11.3 Months |
|---|
| p-value | 0.369509 |
|---|
| Hazard Ratio (HR) | 0.96 (95% CI 0.77–1.20) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.